Low Rates of Insomnia Associated With Flibanserin in Premenopausal Women With Hypoactive Sexual Desire Disorder
ACOG ePoster. Simon J. Apr 27, 2018; 211870
James Simon
James Simon
Login now to access Regular content available to all registered users.

You may also access this content "anytime, anywhere" with the Free MULTILEARNING App for iOS and Android
Abstract
Rate & Comment (0)
Introduction: Flibanserin, a 5-HT1A agonist and 5-HT2A antagonist, is approved for treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. Insomnia is a common side effect of medications that affect central serotonergic mechanisms. This analysis examined the incidence of insomnia associated with flibanserin and other representative medications that affect central serotonergic systems.

Methods: Patient-level data from five 24-week, randomized, double-blind, placebo-controlled, studies in premenopausal women with HSDD were pooled to evaluate the incidence, time to onset, and duration of insomnia with flibanserin treatment. Incidence of insomnia was obtained from clinical trial data reported in the prescribing information for a commonly prescribed selective serotonin reuptake inhibitor (sertraline, steady-state treatment), serotonin-norepinephrine reuptake inhibitor (venlafaxine, steady-state treatment), and triptan (sumatriptan, acute treatment).

Results: In the pooled data (flibanserin 100 mg at bedtime, n=1,543; placebo, n=1,905), most patients (88.2%) were white and mean age was 35.8 years. Mean exposure was 139.0 days with flibanserin and 147.4 days with placebo. The incidence of insomnia was 4.9% with flibanserin and 2.4% with placebo. As context, the incidence of insomnia reported for some commonly used medications that affect the central serotonergic mechanisms ranges from
    This eLearning portal is powered by:
    This eLearning portal is powered by MULTIEPORTAL
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.


Save Settings